Tokyo, June 17 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061927) titled 'Exploratory Study on NAD+ Measurement Techniques Following NMN (Two Types) Intake' on June 17.
Study Type:
Interventional
Study Design:
Basic Design - Parallel
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Dose comparison
Primary Sponsor:
Institute - DHC Corporation
Condition:
Condition - none
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Whole blood NAD levels and eight types of NMN-related metabolites
Basic objectives2 - PK,PD
Intervention:
Interventions/Control_1 - Type 1 NMN 350mg
Interventions/Control_2 - Type 2 NMN 250mg
Eligibility:
Age-lower limit - 35
years-old
Gender - Male and Female
Key inclusion criteria - 1.Healthy individuals
2.Individuals who, having fully understood the purpose and content of the study, consent to participate of their own free will
Key exclusion criteria - 1.Individuals with an acute illness or currently undergoing treatment for such an illness
2.Individuals with a blood disorder
3.Individuals currently suffering from a symptomatic infectious disease on the test day
4.Individuals who regularly consume health supplements containing NMN
5.Individuals who are pregnant or breastfeeding
6.Individuals currently participating in other clinical trials or similar studies
7.Any other individuals deemed unsuitable as subjects by the treating physician or the principal investigator
Target Size - 5
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2026 Year 05 Month 21 Day
Date of IRB - 2026 Year 06 Month 09 Day
Anticipated trial start date - 2026 Year 06 Month 11 Day
Last follow-up date - 2026 Year 07 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070802
Disclaimer: Curated by HT Syndication.
